- Vaccinate male patients. The 9-valent HPV vaccine was associated with meaningful cancer risk reduction in males across a wide age range, reinforcing current recommendations to vaccinate all adolescent boys.
- Earlier vaccination matters, but older adolescents still benefit. The protective association was statistically significant in both the 9–14 and 15–26 age groups, supporting catch-up vaccination in older male patients who have not yet been vaccinated.
- Head and neck cancer is the predominant HPV-related cancer risk in young males. Esophageal, penile, and anal cancer events were too rare in this age group to analyze separately; counseling should reflect that oropharyngeal and related cancers represent the primary measurable risk.
- Observational limitations warrant measured communication. Diagnoses relied on administrative coding without histologic confirmation, vaccination outside participating centers was not captured, and high-risk sexual behavior was likely underascertained — findings should be framed as associational, not causal.
- Sex-neutral vaccination has population-level implications. Where HPV vaccination programs remain female-only, this study adds to the evidence base for expanding access to males, which may reduce the overall burden of HPV-related disease across both sexes.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
